Status:
COMPLETED
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-78 years
Phase:
PHASE3
Brief Summary
The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled w...
Eligibility Criteria
Inclusion
- History of T2DM treated with Metformin
Exclusion
- FPG \>= 260 mg/dL (14.4mmol/L)
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT00728351
Start Date
June 1 2008
Last Update
December 19 2020
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Pine Bluff, Arkansas, United States, 71603
2
Long Beach, California, United States, 90806
3
Denver, Colorado, United States, 80209
4
Bangor, Maine, United States, 04401